Jonathan D. Grinstein

I don’t know who needs to hear this but $ABVX has already showed their cards 1. ATM was oversubscribed, essentially a sweet heart deal 2. Closed in one day (not standard) 3. The MGMT basically said they want to sell if price is right 4. If/when Crohns hits it essentially becomes too big to buy for most companies I don’t see a way forward unless it is a quick sale Reuters reported before latest data follow up multiple buyers The one holdback is - what price? This holdback is solved by one fact and one fact only Multiple bidders = FOMO Biotechs don’t sell, they get bought If you have Crohns hit it is a $10BN revenue It’s basically pay less now vs pay more later if you expect it to hit I absolutely expect one or more pharmas to bid heavily and see Crohns as a call option So what will Abivax MGMT do? You absolutely sell if you can get $220 or more a share For the sweetheart ATM that’s a 76% increase in short time There’s just too much at stake and a MGMT that imo does NOT want to launch a drug